Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Priya Dayananth is active.

Publication


Featured researches published by Priya Dayananth.


Nature Genetics | 2001

A candidate prostate cancer susceptibility gene at chromosome 17p

Sean V. Tavtigian; Jacques Simard; David H.-F. Teng; Vicki Abtin; Michelle L. Baumgard; Audrey Beck; Nicola J. Camp; Arlene Carillo; Yang Chen; Priya Dayananth; Marc Desrochers; Martine Dumont; James M. Farnham; David A. Frank; Cheryl Frye; Siavash Ghaffari; Jamila Gupte; Rong Hu; Diana Iliev; Teresa Janecki; Edward N. Kort; Kirsten Laity; Amber Leavitt; Gilles Leblanc; Jodi Mcarthur-Morrison; Amy Pederson; Brandon Penn; Kelly T. Peterson; Julia Reid; Sam Richards

It is difficult to identify genes that predispose to prostate cancer due to late age at diagnosis, presence of phenocopies within high-risk pedigrees and genetic complexity. A genome-wide scan of large, high-risk pedigrees from Utah has provided evidence for linkage to a locus on chromosome 17p. We carried out positional cloning and mutation screening within the refined interval, identifying a gene, ELAC2, harboring mutations (including a frameshift and a nonconservative missense change) that segregate with prostate cancer in two pedigrees. In addition, two common missense variants in the gene are associated with the occurrence of prostate cancer. ELAC2 is a member of an uncharacterized gene family predicted to encode a metal-dependent hydrolase domain that is conserved among eukaryotes, archaebacteria and eubacteria. The gene product bears amino acid sequence similarity to two better understood protein families, namely the PSO2 (SNM1) DNA interstrand crosslink repair proteins and the 73-kD subunit of mRNA 3′ end cleavage and polyadenylation specificity factor (CPSF73).


Oncogene | 1998

Characterization of a carboxy-terminal BRCA1 interacting protein.

Alexander K. C. Wong; Patricia A. Ormonde; Ralph Pero; Yuan Chen; Lubing Lian; Grant Salada; Simin Berry; Quentin Lawrence; Priya Dayananth; Phuong Ha; Sean V. Tavtigian; David H.-F. Teng; Paul L. Bartel

There are several lines of evidence indicating that the carboxy-terminal region of the tumor suppressor protein BRCA1 is a functionally significant domain. Using the yeast two-hybrid and in vitro biochemical assays, we show that a protein, CtIP, interacts specifically with the carboxy-terminal segment of human BRCA1 from residues 1602–1863. A germ line truncation mutation, Y1853ter, that removes the last 11 amino acids from the carboxy-terminus of BRCA1, abolishes not only its transcriptional activation function, but also binding to CtIP. The function of CtIP is unknown, but its reported association with a transcriptional repressor CtBP lends further support that it may have a role in transcription. A sequence based screen of a panel of 89 tumor cell line cDNAs for mutations in the CtIP coding region identified five missense variants. In the pancreatic carcinoma cell line, BxPC3, the non-conservative lysine to glutamic acid change at codon 337 is accompanied with apparent loss of heterozygosity or non-expression of the wild type allele. Thus it is plausible that CtIP may itself be a tumor suppressor acting in the same pathway as BRCA1.


Journal of Medicinal Chemistry | 2014

Discovery of Novel, Dual Mechanism ERK Inhibitors by Affinity Selection Screening of an Inactive Kinase

Yongqi Deng; Gerald W. Shipps; Alan B. Cooper; Jessie M. English; D. Allen Annis; Donna Carr; Yang Nan; Tong Wang; Hugh Y. Zhu; Cheng-Chi Chuang; Priya Dayananth; Alan Hruza; Li Xiao; Weihong Jin; Paul Kirschmeier; William T. Windsor; Ahmed A. Samatar

An affinity-based mass spectrometry screening technology was used to identify novel binders to both nonphosphorylated and phosphorylated ERK2. Screening of inactive ERK2 identified a pyrrolidine analogue 1 that bound to both nonphosphorylated and phosphorylated ERK2 and inhibited ERK2 kinase activity. Chemical optimization identified compound 4 as a novel, potent, and highly selective ERK1,2 inhibitor which not only demonstrated inhibition of phosphorylation of ERK substrate p90RSK but also demonstrated inhibition of ERK1,2 phosphorylation on the activation loop. X-ray cocrystallography revealed that upon binding of compound 4 to ERK2, Tyr34 undergoes a rotation (flip) along with a shift in the poly-Gly rich loop to create a new binding pocket into which 4 can bind. This new binding mode represents a novel mechanism by which high affinity ATP-competitive compounds may achieve excellent kinase selectivity.


Journal of Molecular Evolution | 1995

Comparative analysis of Homo sapiens and Mus musculus cyclin-dependent kinase (CDK) inhibitor genes P16 (MTS1) and P15 (MTS2)

Ping Jiang; Steven Stone; Roger Wagner; Susan L. Wang; Priya Dayananth; Christine A. Kozak; Barbara J. Wold; Alexander Kamb

Cyclin-dependent kinase inhibitors are a growing family of molecules that regulate important transitions in the cell cycle. At least one of these molecules, p16, has been implicated in human tumorigenesis while its close homolog, p15, is induced by cell contact and transforming growth factor-β (TGF-β). To investigate the evolutionary and functional features of p15 and p16, we have isolated mouse (Mus musculus) homologs of each gene. Comparative analysis of these sequences provides evidence that the genes have similar functions in mouse and human. In addition, the comparison suggests that a gene conversion event is part of the evolution of the human p15 and p16 genes.


Science | 1994

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

Yoshio Miki; Jeff Swensen; Donna M. Shattuck-Eidens; P. Andrew Futreal; Keith D. Harshman; Sean V. Tavtigian; Qingyun Liu; Charles Cochran; L. Michelle Bennett; Wei Ding; Russell Bell; Judith Rosenthal; Charles Hussey; Thanh Tran; Melody McClure; Cheryl Frye; Tom Hattier; Robert Phelps; Astrid Haugen-Strano; Harold Katcher; Kazuko Yakumo; Zahra Gholami; Daniel Shaffer; Steven Stone; Steven Bayer; Christian Wray; Robert Bogden; Priya Dayananth; John H. Ward; Patricia N. Tonin


Cancer Research | 1995

Complex Structure and Regulation of the P16 (MTS1) Locus

Steven Stone; Ping Jiang; Priya Dayananth; Sean V. Tavtigian; Harold Katcher; David Parry; Gordon Peters; Alexander Kamb


Oncogene | 1995

Genomic structure, expression and mutational analysis of the P15 (MTS2) gene

S. Stone; Priya Dayananth; Ping Jiang; Jane Weaver-Feldhaus; S. V. Tavtigian; L. Cannon-Albright; A. Kamb


Cancer Research | 1996

Reversible, p16-mediated cell cycle arrest as protection from chemotherapy.

Steven Stone; Priya Dayananth; Alexander Kamb


Human Molecular Genetics | 1995

Comparison of the positional cloning methods used to isolate the BRCA1 gene

Keith D. Harshman; Russell Bell; Judith Rosenthal; Harold Katcher; Yoshio MlKl; Jeff Swenson; Zahra Gholami; Cheryl Frye; Wei Ding; Priya Dayananth; Ken Eddington; Franklin H. Norris; Pamela K. Bristow; Robert Phelps; Thomas Haltier; Steven Stone; Daniel Shaffer; Steven Bayer; Charles Hussey; Thanh Tran; Katherine K. Richardson; Brad Dehoff; Mei Lai; Paul Robert Rosteck; Mark H. Skolnick; Donna M. Shattuck-Eidens; Alexander Kamb


Archive | 2008

A StrongCandidateforthe Breastand OvarianCancer Susceptibility Gene BRCA1

Yoshio Miki; Jeff Swensen; Keith D. Harshman; Qingyun Liu; Charles Cochran; Russell Bell; Judith Rosenthal; Charles Hussey; Cheryl Frye; Robert Phelps; Astrid Haugen-Strano; Harold Katcher; Christian Wray; Robert Bogden; Priya Dayananth; Patricia N. Tonin; Cathryn M. Lewis; Alexander Kamb

Collaboration


Dive into the Priya Dayananth's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge